New Street Research analyst Soomit Datta maintains MercadoLibre (NASDAQ:MELI) with a Buy and lowers the price target from $1700 to $1100.
Wells Fargo Maintains Overweight on Tandem Diabetes Care, Lowers Price Target to $82
Wells Fargo analyst Lawrence Biegelsen maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Overweight and lowers the price target from $166 to $82.